Lumida
/VCYT
⌘K
Veracyte Inc

Veracyte Inc

VCYT
$59.13USD↓-0.15%-0.09 today

MARKET CAP

4.7B

P/E (TTM)

54.2x

FWD P/E

53.0x

DAY RANGE

$57 – $59

52W RANGE

$23
$61

AI Summary

Stalk
StalkMedium

VCYT remains in a Stage 2 advancing regime with a clear higher-highs/higher-lows sequence above rising EMAs and the 50DMA. The primary Bullish Exhaustion pattern at marginal highs and elevated overbought readings on RSI and the Options Score signal waning near-term momentum. Price sits at resistance with long upper wicks and is extended above the EMAs, suggesting patience for a pullback into the 9/21 EMA zone before engagement. Medium-term structure is bullish, but timing conditions favor a deferred entry until support holds.

  • ↑Q1 revenue $139.1M (+21% YoY); full-year guidance raised to $582–592M
  • ↑Decipher test volume up 24% YoY to ~28,000 tests
  • ↓Negative earnings yield and ~4.5% overvaluation weigh on valuation appeal
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Veracyte, Inc. (NASDAQ: VCYT) is a leader in the precision medicine sector, specializing in advanced genomic testing solutions aimed at enhancing cancer diagnosis and treatment decision-making. With prominent products like Decipher and Affirma, Veracyte operates at the forefront of oncology diagnostics, focusing on molecular testing for various cancer types, including prostate and thyroid cancers. The company is well-positioned to benefit from the ongoing trends in personalized medicine and the rising demand for actionable data in cancer care.

Bull says

  • ↑Q1 revenue $139.1M (+21% YoY); full-year guidance raised to $582–592M
  • ↑Decipher test volume up 24% YoY to ~28,000 tests
  • ↑Gross margin 75.7% and adjusted EBITDA margin 30.8% after lab workflow gains
  • ↑2026 launches of Prosigna (225K breast cancer patients) and TrueMRD target new markets
  • ↑Strong growth momentum and upward earnings revisions; low leverage supports stability
  • ↑Zacks Strong Buy and Guggenheim $65 price target underscore institutional confidence

Bear says

  • ↓Negative earnings yield and ~4.5% overvaluation weigh on valuation appeal
  • ↓Low 13F ownership signals weak institutional support
  • ↓Regulatory approvals for Prosigna and TrueMRD face potential delays
  • ↓Intense competition from digital pathology and liquid biopsy may erode market share
  • ↓Stock volatility and interest-rate sensitivity could magnify downturns
  • ↓Elevated short interest reflects investor skepticism on growth outlook

Investment themes with VCYT

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026bullish

Transcript signals

Bull points

  • In the first quarter, we delivered strong double-digit revenue and volume growth, exceeded our profitability expectations, and continued advancing key catalysts that position us well for long-term growth.
  • We revitalized the firma, made Decipher the top prostate cancer gene expression test, increased lab capacity threefold, improved turnaround time and the no result rate, and surpassed the 25% adjusted EBITDA margin.
  • Since our acquisition in early 2021, the Decipher business has delivered consistent growth of more than 20% quarter after quarter, with approximately 28,000 tests delivered in the first quarter, representing 24% year-over-year volume growth.
Read full transcript analysis ›